FDA's 2025 drug enforcement program grew bigger, broader, more centralized

A Hogan Lovells analysis of FDA human drug enforcement activity in 2025 reports a substantially larger, more centralized program with a shifted mix of enforcement activity, a trend regulatory counsel should factor into compliance planning.